CVRx, Inc.

CVRx, Inc.

NNASDAQ:CVRX
0.61
USD
+0.01
(+0.92%)
-2.00EPS
46.62MMarket Cap
Feb 17Next Earn
CVRx, Inc.
NASDAQ:CVRX
(Nasdaq Stock Market)

Recent

price

0.61

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
USD
0.6
0.31
1.26
1.09
1.89
2.27
2.17
2.27
Revenue per Share
-1.41
-0.73
-4.16
-2.02
-1.99
-2.65
-2.04
-2
Basic EPS, GAAP
-1.25
-0.85
-2.79
-2.11
-1.91
-1.79
-1.56
-1.58
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-15.05
-14.41
7.16
5.29
3.64
2.81
1.49
0.52
Book Value per Share
-15.05
-14.41
7.16
5.29
3.64
2.81
1.49
0.52
Tangible Book Value per Share
10
19
10
21
21
23
26
27
Basic Weighted Avg Shares
6
6
13
22
39
51
57
60
Sales/Revenue/Turnover
-162.92
-190.22
-199.2
-189.27
-109.69
-115.98
-90.49
-81.9
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
Depreciation Expense
-15
-14
-43
-41
-41
-60
-53
-53
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-233.87
-233.09
-330.45
-184.38
-104.85
-116.91
-94.1
-88.28
Profit Margin (%)
20
56
145
115
104
119
88
73
Working Capital
19
19
- -
7
30
50
50
59
LT Debt
-279
-293
146
109
76
71
39
14
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-32.47
-44.51
-81.58
-96.59
-172.17
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
58
59
59
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
27
27
Market Capitalization
250
137
47

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
97
89
85
Cash, Cash Equivalents & STI
72
65
59
Accounts Receivable, Net
9
9
10
Inventories
12
13
14
Total Current Liabilities
9
11
13
Payables & Accruals
6
7
8
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-51.3%
-44.66%
Free Cash Flow
- -
24.08%
0.6%
Net Income, GAAP
- -
47.08%
-11.1%
Sales/Revenue/Turnover
- -
60.72%
10.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11
12
13
15
51
2025
12
14
15
16
57
2026
15
16
14
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
-0.65
-0.57
-0.43
-2.65
2025
-0.53
-0.57
-0.49
-0.46
-2.04
2026
-0.5
-0.53
-0.52
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
CVRx, Inc. is a commercial-stage medical device company specializing in the development, manufacturing, and commercialization of neuromodulation solutions for patients with cardiovascular diseases. The company’s core product is the Barostim system, an implantable device designed to treat hypertension and heart failure by electrically stimulating the body's natural baroreceptors to regulate blood pressure and cardiovascular function. The product portfolio includes the second-generation Barostim Neo2 implantable pulse generator and associated implantable systems, which provide personalized, non-destructive, and reversible treatment with 100% patient compliance. CVRx distributes its products primarily through a direct sales force in the United States, supported by over 250 active implanting centers and an expanding footprint of 48 sales territories. Founded in 2001 and headquartered in Minneapolis, Minnesota, CVRx operates primarily in the U.S. market with ongoing clinical evaluations and regulatory developments in Europe. The company targets patients with resistant hypertension and heart failure, with a strategic focus on increasing physician and patient awareness, improving access to therapy, and expanding clinical evidence. Recent developments include the launch of their second-generation Barostim Neo2 pulse generator in late 2022, offering enhanced treatment options for heart failure symptoms. In 2024 and 2025, CVRx demonstrated robust commercial growth, increasing U.S. active implanting centers from 208 to 250 and expanding sales territories. CVRx’s latest major strategic activities include raising $12.8 million through at-the-market offerings to support commercial expansion and marketing initiatives focused on salesforce growth and territory development. The company achieved 35% revenue growth in 2024 with forecasted total revenue between $63 million and $65 million for 2025. CVRx continues investment in enhancing its sales and marketing organization to support broader market penetration and patient uptake of Barostim therapy. These operational expansions position CVRx as a leader in implantable neuromodulation therapies for cardiovascular conditions. Overall, CVRx operates in the medical device and healthcare industry, with a clear commercial-stage focus on innovative neuromodulation treatments for cardiovascular diseases. The company maintains a strong emphasis on product innovation, clinical validation, and geographic expansion within the United States, while also exploring opportunities in European markets. CVRx is publicly traded on NASDAQ under the ticker CVRX and maintains proprietary technology centered on baroreceptor activation for improved cardiovascular health outcomes.

Company News

  • ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRX

  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. (NASDAQ: CVRX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. ( CVRX) - Investors Who Suffered Losses Are Encouraged to Contact the Firm

  • CVRX INVESTOR ALERT: Securities Class Action Filed, Hagens Berman Urges CVRx, Inc. Investors with Substantial Losses to Contact Firm Ahead of January 8, 2027 Lead Plaintiff Deadline

  • Securities Fraud Class Action Filed Against CVRx, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

  • Levi & Korsinsky Reminds CVRx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of January 8, 2027 - CVRX

  • ROSEN, SKILLED INVESTOR COUNSEL, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRX

  • ROSEN, LEADING INVESTOR COUNSEL, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRX

  • ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CVRX

  • Securities Fraud Lawsuit Filed Against CVRx, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

  • DEADLINE ALERT for Arbor Realty Trust, Inc. (ABR), NVIDIA Corporation (NVDA), and CVRx, Inc. (CVRX): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions

  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. (NASDAQ: CVRX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm

  • HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx, Inc. (CVRX) Investors with Substantial Losses to Contact Firm, Securities Class Action Filed

  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against CVRx, Inc. (NASDAQ: CVRX) -- Investors Who Suffered Losses Are Encouraged to Contact the Firm.

  • CVRX Investors Have Opportunity to Lead CVRx, Inc. Securities Fraud Lawsuit with SBS Law

  • CVRX Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the CVRx, Inc. Class Action Lawsuit

  • CVRX SHAREHOLDER NOTICE: CVRx, Inc. Investors with Substantial Losses Have Opportunity to Lead the CVRx Class Action Lawsuit

  • ROSEN, SKILLED INVESTOR COUNSEL, Encourages CVRx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CVRX

  • CVRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in CVRx, Inc. Securities Lawsuit - Contact SueWallSt

  • Kaplan Fox Encourages CVRx, Inc. (CVRX) Investors with Significant Losses to Contact the Firm Before January 8, 2027